ArticleClinical epigenetics2025

miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting.

Yilan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.